000268622 001__ 268622
000268622 005__ 20240403110107.0
000268622 0247_ $$2pmc$$apmc:PMC10928350
000268622 0247_ $$2doi$$a10.1002/mdc3.13937
000268622 0247_ $$2pmid$$apmid:38468507
000268622 0247_ $$2altmetric$$aaltmetric:156898062
000268622 037__ $$aDZNE-2024-00277
000268622 041__ $$aEnglish
000268622 082__ $$a610
000268622 1001_ $$00000-0002-0870-8105$$aSchnalke, Nils$$b0$$eFirst author
000268622 245__ $$aValidation of the Distress Thermometer as a Screening Tool for Psychosocial Distress and Resilience in Parkinson's Disease.
000268622 260__ $$aNew York, NY$$bWiley$$c2024
000268622 3367_ $$2DRIVER$$aarticle
000268622 3367_ $$2DataCite$$aOutput Types/Journal article
000268622 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711025293_32503
000268622 3367_ $$2BibTeX$$aARTICLE
000268622 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000268622 3367_ $$00$$2EndNote$$aJournal Article
000268622 520__ $$aParkinson's disease (PD) is associated with psychosocial distress that affects patients' quality of life. The distress thermometer (DT) is an 11-point visual analogue scale that is used as a screening tool for the assessment of psychosocial distress, originally developed for oncological diseases.To validate the DT for PD and to explore contributing factors.The DT scale was administered to 105 people with Parkinson's Disease (PwPD). Along with it, we assessed motor symptoms (Unified Parkinson's Disease Rating Scale part III [UPDRS III], Hoehn and Yahr-stage [H&Y]), non-motor symptoms (Non-motor Symptom Questionnaire [NMSQ]), anxiety and depression (Hospital Anxiety and Depression Scale [HADS], Fear of Progression-Questionnaire Short Form [FOP-Q-SF], Generalized Anxiety Disorder Scale-7 [GAD-7], 9-question Patient Health Questionnaire [PHQ-9]), the feeling of hope (Herth Hope Index [HHI]) and quality of life (Schedule for the Evaluation of Individual Quality of Life [SEIQoL]).With a cut-off of 4, the DT identified PwPD with distress with a sensitivity of 97% and a specificity of 38%. With this cut-off, the DT will yield false negative results in 1 out of 100 cases. Factor analyses and a random forest regression of the dataset revealed that distress can be predicted by two factors, which we termed 'anxiety' and 'depression/resilience/motor symptoms'.The DT is an ultra-short and reliable screening tool for distress in PwPD. DT values below 4 rule out distress with a high degree of certainty. Anxiety and depression are important factors in distress but are counterbalanced by the individuals' psychological resilience.
000268622 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000268622 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000268622 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000268622 650_7 $$2Other$$aParkinson's disease
000268622 650_7 $$2Other$$aanxiety
000268622 650_7 $$2Other$$adepression
000268622 650_7 $$2Other$$adistress
000268622 650_7 $$2Other$$ascreening tool
000268622 650_2 $$2MeSH$$aHumans
000268622 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000268622 650_2 $$2MeSH$$aResilience, Psychological
000268622 650_2 $$2MeSH$$aDepression: diagnosis
000268622 650_2 $$2MeSH$$aQuality of Life: psychology
000268622 650_2 $$2MeSH$$aThermometers
000268622 650_2 $$2MeSH$$aVisual Analog Scale
000268622 7001_ $$aTekampe, Esther$$b1
000268622 7001_ $$0P:(DE-2719)9000884$$aFeige, Tim$$b2$$udzne
000268622 7001_ $$0P:(DE-2719)9001473$$aFrank, Anika$$b3
000268622 7001_ $$aReichmann, Heinz$$b4
000268622 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Björn$$b5$$udzne
000268622 7001_ $$00000-0003-2133-714X$$aD'Souza, Simone$$b6$$eLast author
000268622 773__ $$0PERI:(DE-600)2772809-2$$a10.1002/mdc3.13937$$gVol. 11, no. 3, p. 257 - 264$$n3$$p257 - 264$$tMovement disorders clinical practice$$v11$$x2330-1619$$y2024
000268622 8564_ $$uhttps://pub.dzne.de/record/268622/files/DZNE-2024-00277%20SUP.docx
000268622 8564_ $$uhttps://pub.dzne.de/record/268622/files/DZNE-2024-00277.pdf$$yOpenAccess
000268622 8564_ $$uhttps://pub.dzne.de/record/268622/files/DZNE-2024-00277%20SUP.doc
000268622 8564_ $$uhttps://pub.dzne.de/record/268622/files/DZNE-2024-00277%20SUP.odt
000268622 8564_ $$uhttps://pub.dzne.de/record/268622/files/DZNE-2024-00277%20SUP.pdf
000268622 8564_ $$uhttps://pub.dzne.de/record/268622/files/DZNE-2024-00277.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000268622 909CO $$ooai:pub.dzne.de:268622$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000268622 9101_ $$0I:(DE-588)1065079516$$60000-0002-0870-8105$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000268622 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000884$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000268622 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001473$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000268622 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000268622 9101_ $$0I:(DE-588)1065079516$$60000-0003-2133-714X$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000268622 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000268622 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000268622 9141_ $$y2024
000268622 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000268622 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000268622 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000268622 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000268622 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOV DISORD CLIN PRAC : 2022$$d2023-08-25
000268622 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-08-25$$wger
000268622 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000268622 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000268622 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000268622 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000268622 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000268622 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000268622 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000268622 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000268622 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000268622 9201_ $$0I:(DE-2719)1710012$$kAG Falkenburger$$lTranslational Parkinson Research$$x0
000268622 9201_ $$0I:(DE-2719)1710001$$kAG Kempermann$$lAdult Neurogenesis$$x1
000268622 980__ $$ajournal
000268622 980__ $$aVDB
000268622 980__ $$aUNRESTRICTED
000268622 980__ $$aI:(DE-2719)1710012
000268622 980__ $$aI:(DE-2719)1710001
000268622 9801_ $$aFullTexts